Cutting-edge cell therapies from Novartis and Gilead aren't direct rivals for now, but with a new FDA filing, that could change—and soon.
Novartis' $3.9B deal for Advanced Accelerator Applications comes with a blockbuster-to-be, Lutathera, that could follow in Sandostatin's footsteps.
The CDC committee in charge of vaccination policy in the U.S. endorsed GlaxoSmithKline's Shingrix over the older shot, Merck's Zostavax.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.
Bristol-Myers aims to get its I-O med Opdivo to cancer patients as early as possible, and a new approval in melanoma would be a step in that direction.
FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.
Flexion's raring to launch its knee injection Zilretta, and it's floating a $100 million-plus stock offering to make that happen.
A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.
Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.